sacituzumab govitecan + hydroxychloroquine

This combination therapy consists of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC), and hydroxychloroquine, an autophagy inhibitor. Sacituzumab govitecan is composed of a humanized monoclonal antibody (sacituzumab) linked to the topoisomerase I inhibitor payload SN-38 (govitecan) via a pH-sensitive linker. It targets the Trophoblast cell-surface antigen 2 (Trop-2), which is frequently overexpressed in various solid tumors, including breast cancer. Hydroxychloroquine is an antimalarial agent that also acts as an autophagy inhibitor by preventing lysosomal acidification. In the context of advanced breast cancer, hydroxychloroquine is hypothesized to act synergistically with ADCs by inhibiting autophagy, a survival mechanism that cancer cells may employ to resist the cytotoxic effects of the ADC payload. This specific combination is being investigated in a Phase I/II clinical trial sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University for patients with advanced breast cancer who have progressed on prior therapies.

Brand names

Trodelvy + Plaquenil

Other names

SG + HCQ